-
Clorox is facing expectations for a year-over-year earnings and revenue decline for its June 2026 quarter, with analysts forecasting quarterly earnings of US$1.64 per share and revenues of US$1.91 billion ahead of the August 3 earnings call that has now passed.
-
An interesting angle is that the company’s weaker earnings outlook is accompanied by a bearish analyst stance, including a negative Earnings ESP and a lower independent ranking, which together highlight concerns about the near-term earnings trajectory.
-
We’ll now examine how this anticipated earnings and revenue weakness, combined with more cautious analyst sentiment, may reshape Clorox’s investment narrative.
AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part – they are all under $10b in market cap – there’s still time to get in early.
Clorox Investment Narrative Recap
To own Clorox, you generally have to believe its core brands and new product platforms can still support solid cash generation despite slower categories and rising competition. The latest expectation of a sharp earnings and revenue drop for the June 2026 quarter, alongside more cautious analyst sentiment, reinforces that the key short term catalyst is execution on efficiency and innovation, while the biggest risk remains pressure on margins from value seeking consumers and aggressive rivals.
In that context, Clorox’s April 30 guidance cut for FY2026, with net sales now expected to fall about 6% and diluted EPS guided to US$4.78 to US$4.98, is highly relevant. It ties the near term earnings weakness to tougher demand and cost headwinds, even after factoring in the GOJO acquisition and VMS divestiture, and puts more weight on whether the ERP rollout and product launches in late fiscal 2026 can offset these pressures.
Yet behind these headline numbers, there is a growing risk investors should be aware of around…
Read the full narrative on Clorox (it’s free!)
Clorox’s narrative projects $7.9 billion revenue and $886.0 million earnings by 2029. This requires 5.5% yearly revenue growth and about a $130 million earnings increase from $756.0 million today.
Uncover how Clorox’s forecasts yield a $105.29 fair value, a 5% upside to its current price.
Exploring Other Perspectives
Some of the most optimistic analysts were previously assuming Clorox could lift earnings to about US$999 million on US$8.1 billion of revenue by 2029, which is a very different story from today’s expected 42.9% quarterly EPS decline and softer guidance, and shows how widely opinions can differ and may still change as new information comes in.
